Overview

Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma

Status:
Completed

Trial end date:
2012-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to establish the safety and optimal dose of orally administered PCI-32765 in patients with recurrent B cell lymphoma.

Phase:

Phase 1

Details

Lead Sponsor:

Pharmacyclics LLC.